Marshall Wace’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Marshall Wace’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,123	Closed	-$61K	–	3642
2022 Q3	$61K	Buy	+10,123	New	+$57.4K	﹤0.01%	3226
2021 Q3	–	Sell	-70,247	Closed	-$495K	–	3568
2021 Q2	$495K	Sell	70,247 -9,541	-12%	-$51.4K	﹤0.01%	2135
2021 Q1	$472K	Buy	+79,788	New	+$483K	﹤0.01%	1969

Other funds holding STSA

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Marshall Wace's STSA Position: Q4 2022 in Review

Marshall Wace sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 10,123 shares — an estimated $61K sold.

Marshall Wace first reported a position in STSA in Q1 2021 and held it in 3 quarters. The position peaked at $495K in Q2 2021. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

Marshall Wace reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Marshall Wace sold 10,123 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $61K.
Marshall Wace first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
Marshall Wace's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $495K in Q2 2021.
33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.